Drug dosage in children with reduced renal function

Drug dosing in paediatric nephrology requires multiple considerations and is therefore time-consuming and error-prone. This review combines dose adjustment guidelines for children with renal failure and information on the immature renal function of neonates and premature babies in order to help both paediatric nephrologists and neonatologists estimate drug doses for their patients.

[1]  A. Rane,et al.  Clonazepam serum protein binding during development , 1984, Clinical pharmacology and therapeutics.

[2]  L. Weber,et al.  Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. , 1998, Journal of the American Society of Nephrology : JASN.

[3]  Á. Pazos,et al.  Aminergic receptors during the development of the human brain: the contribution of in vitro imaging techniques , 2001, Journal of Chemical Neuroanatomy.

[4]  C. Huriet.  [Drug-induced nephropathies]. , 1967, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.

[5]  A. Wood,et al.  Changes in plasma drug binding and alpha 1-acid glycoprotein in mother and newborn infant. , 1981, Clinical pharmacology and therapeutics.

[6]  C. Stewart,et al.  Effect of maturation on drug disposition in pediatric patients. , 1987, Clinical pharmacy.

[7]  F. Keller,et al.  Arzneimitteldosierung bei Niereninsuffizienz—Fallstricke und Hilfen , 2004, Medizinische Klinik.

[8]  A. Wood,et al.  Changes in plasma drug binding and α1‐acid glycoprotein in mother and newborn infant , 1981 .

[9]  S B Heymsfield,et al.  Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. , 1983, The American journal of clinical nutrition.

[10]  W. Oh,et al.  Influence of gestational age on serum levels of alpha-1 fetoprotein, IgG globulin, and albumin in newborn infants. , 1973, The Journal of pediatrics.

[11]  M. Paller.  Drug-induced nephropathies. , 1990, The Medical clinics of North America.

[12]  A. Dasgupta,et al.  Elevated free fatty acid concentrations in lipemic sera reduce protein binding of valproic acid significantly more than phenytoin. , 1997, The American journal of the medical sciences.

[13]  L. Heitlinger,et al.  Impact of development of the gastrointestinal tract on infant feeding. , 1983, The Journal of pediatrics.

[14]  B. Warady,et al.  Consensus Guidelines for the Treatment of Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[15]  B. Piraino,et al.  Reviews and Original Articles , 1996 .

[16]  C. Fawer,et al.  Maturation of renal function in full-term and premature neonates. , 1979, Helvetica paediatrica acta.

[17]  C. Yee,et al.  Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin , 2002, The Pediatric infectious disease journal.

[18]  R. Jelliffe,et al.  Recombinant Human Erythropoietin for the Treatment of Renal Anaemia in Children for Bodyweight-Adjusted Dosage , 2004 .

[19]  Á. Pazos,et al.  Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain , 2003, The European journal of neuroscience.

[20]  A. Levey,et al.  Measurement of renal function in chronic renal disease. , 1990, Kidney international.

[21]  B. Piraino,et al.  Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update. , 1996, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[22]  A. Rane,et al.  Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants. , 1971, The Journal of pediatrics.

[23]  L. Weber,et al.  Successful Withdrawal of Steroids in Pediatric Renal Transplant Recipients Receiving Cyclosporine A and Mycophenolate Mofetil Treatment: Results after Four Years , 2004, Transplantation.

[24]  M. Daschner,et al.  Pharmakotherapie bei Niereninsuffizienz , 2002 .

[25]  R. Farinotti,et al.  Morphine Pharmacokinetics in Renal Failure , 1987, Anesthesiology.

[26]  Robert J. Anderson,et al.  Clinical use of drugs in renal failure , 1976 .

[27]  Eckard Oberdisse,et al.  Pharmakologie und Toxikologie: Arzneimittelwirkungen verstehen – Medikamente gezielt einsetzen , 2006 .

[28]  Stewart Cf,et al.  Effect of maturation on drug disposition in pediatric patients. , 1987 .

[29]  R. Macholz.  Allgemeine und spezielle Pharmakologie und Toxikologie, 5. Aufl. Herausgegeben von W. Forth, D. Henschler und W. Rummel. 877 Seiten, zahlr. Abb. und Tab. B. I. Wissenschaftsverlag, Mannheim, Wien, Zürich 1987. Preis: 124,— DM. , 1988 .

[30]  D. Evans,et al.  Drugs and the kidney. , 1980, British journal of hospital medicine.

[31]  F. Schaefer,et al.  Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis-associated peritonitis. The Mid-European Pediatric Peritoneal Dialysis Study Group (MEPPS). , 1999, Journal of the American Society of Nephrology : JASN.